IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the instant application. The present status of each claim is indicated in parentheses following the claim number. An instruction line precedes each claim that is amended, cancelled, or added by the instant paper.

1-13 CANCELLED

Please amend claim 14 as follows:

- 14. (CURRENTLY AMENDED) An in vitro method for producing

 Langerhans _type_dendriticdendritic Langerhans cells,
 said method comprising:
 - a. culturing cells selected from the group consisting of peripheral blood monocytes and bone marrow cells in a medium containing <u>mammalian</u> platelets; and
 - b. incubating the culture at about 30°C to about 40°C for a period sufficient to enable formation of mature <u>Langerhans_type_dendritic</u>dendritic
 Langerhans cells,

wherein the medium omits an exogenous cytokine.

- 15. (PREVIOUSLY PRESENTED) The method as claimed in claim
 14, wherein the exogenous cytokine is granulocyte
 macrophage colony stimulating factor or interleukin-4.
- 16. (PREVIOUSLY PRESENTED) The method as claimed in claim14 wherein the medium comprises RPMI-1640.
- 17. (PREVIOUSLY PRESENTED) The method as claimed in claim
 14 wherein the cells are cultured for a period of
 about 2 to about 8 days.
- 18. (PREVIOUSLY PRESENTED) The method as claimed in claim
 14 wherein the medium further comprises fetal calf
 serum.
- 19. (PREVIOUSLY PRESENTED) The method as claimed in claim
 18, wherein the medium contains at least about 2%
 fetal calf serum.
- 20. (PREVIOUSLY PRESENTED) The method as claimed in claim
 19, wherein the fetal calf serum is about 10%.

Please amend claim 21 as follows:

21. (CURRENTLY AMENDED) The method as claimed in claim 14 wherein human platelets are added to the medium to

develop <u>Langerhans _type_dendritie</u>dendritic <u>Langerhans</u> cells.

Please amend claim 22 as follows:

22. (CURRENTLY AMENDED) The method as claimed in claim 14 wherein rat platelets are added to the medium containing mice blood cells to develop Langerhans = type_dendritic dendriticdendritic Langerhans cells.

Please amend claim 23 as follows:

- 23. (CURRENTLY AMENDED) A method for producing Langerhans

 _type_dendritiedendritic Langerhans cells in vitro

 comprising:
 - a. preparing peripheral blood monocytes and/or bone marrow cells; and
 - b. culturing the peripheral blood monocytes or the bone marrow cells with platelets of the same species in a culture medium lacking an exogenous cytokine such that Langerhans = type dendritic dendriticdendritic Langerhans cells are produced.

Please amend claim 24 as follows:

24. (CURRENTLY AMENDED) The method of claim 23 further comprising analyzing the morphology of human

Langerhans _type_dendriticdendritic Langerhans cells produced.

Please amend claim 25 as follows:

25. (CURRENTLY AMENDED) The method of claim 23 further comprising analyzing the Langerhans _type dendritiedendritic Langerhans cells produced by flow cytometry.

Please amend claim 26 as follows:

26. (CURRENTLY AMENDED) The method of claim 23 wherein the peripheral blood monocytes, the platelets, and the <u>Langerhans _type_dendriticdendritic Langerhans</u> cells produced are human.

6

Please amend claim 27 as follows:

27. (CURRENTLY AMENDED) The method of claim 14
wherein the bone marrow cells are mouse bone marrow cells, the platelets are rat platelets, and the

Langerhans _type_dendriticdendritic Langerhans cells produced are mouse Langerhans _type_dendritic

Langerhans cells.

Please amend claim 28 as follows:

- 28. (CURRENTLY AMENDED) An in vitro method for producing Langerhans type dendritiedendritic Langerhans cells, said method comprising:
 - a. culturing cells selected from the group consisting of peripheral blood monocytes and bone marrow cells in a medium containing <u>mammalian</u> platelets; and
 - b. incubating the culture at about 30°C to about 40°C for a period sufficient to enable formation of mature Langerhans type dendritic <u>Langerhans cells</u>.

Please amend claim 29 as follows:

- 29. (CURRENTLY AMENDED) A method for producing

 Langerhans type dendritic dendritic Langerhans cells in vitro comprising:
 - a. preparing peripheral blood monocytes and/or bone
 marrow cells; and
 - b. culturing the peripheral blood monocytes or the bone marrow cells with platelets of the same species in a culture medium such that Langerhans type dendritiedendritic Langerhans cells are produced.

Please amend claim 30 as follows:

- 30. (CURRENTLY AMENDED) A method for producing

 Langerhans type dendritic dendritic Langerhans cells in vitro comprising:
 - a. preparing peripheral blood monocytes and/or bone marrow cells; and
 - b. culturing the peripheral blood monocytes or the bone marrow cells with platelets in a culture

medium such that Langerhans type

dendritiedendritic Langerhans cells are produced,

wherein the peripheral blood monocytes and/or bone marrow cells and the platelets may be independently selected from the group of rat cells and mouse cells.

- 31. (PREVIOUSLY PRESENTED) The method of claim 30, wherein the culture medium lacks an exogenous cytokine.
- 32. (WITHDRAWN) A method for producing mature dendritic cells in vitro comprising:
 - a. preparing peripheral blood monocytes and/or bone
 marrow cells; and
 - b. culturing the peripheral blood monocytes or the bone marrow cells with platelets of the same species in a culture medium such that mature dendritic cells are produced,

wherein more than about 50% of the mature dendritic cells have dendritic processes and display reactivity to anti-HLA-DR, anti-CD40, and anti-CD86 monoclonal antibodies and less than about 20% of the mature

9

- dendritic cells display reactivity to anti-CD1a, anti-CD80, and anti-CD83 monoclonal antibodies.
- 33. (WITHDRAWN) The method of claim 32, wherein the culture medium lacks an exogenous cytokine.
- 34. (NEW) The method of claim 23 wherein the peripheral blood monocytes are human peripheral blood monocytes, the platelets are human platelets, and the dendritic Langerhans cells produced are human dendritic Langerhans cells.